Brigatinib in Patients With Anaplastic Lymphoma Kinase-Positive (ALK+), Advanced Non–Small-Cell Lung Cancer (NSCLC) Progressed on Alectinib or Ceritinib (2002), NCT03535740
PURPOSE OF THIS CLINICAL RESEARCH TRIAL
The primary purpose of this study is to determine the efficacy of brigatinib by confirmed objective response rate (ORR) by response evaluation criteria in solid tumors (Response Evaluation Criteria in Solid Tumors [RECIST]), in participants with ALK+ locally advanced or metastatic NSCLC whose disease has progressed on therapy with alectinib or ceritinib.
MORE DETAILS ON THIS TRIAL:
18076 / NCT03535740 / Open 12-6-2018 / STAR / PI TBD
TRIAL AVAILABLE AT THESE LOCATIONS
This STAR trial can be opened at any RMCC location as patients are identified.